Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drugs in Development, 2021

September 2021 | 73 pages | ID: G335719C1DC9EN
Global Markets Direct

Abstracts

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drugs in Development, 2021

SUMMARY

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase - Drugs In Development, 2021, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 1, 4 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Diabetes and Obesity.

Furthermore, this report also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
• The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development
Eli Lilly and Co
Hua Medicine Shanghai Ltd
Impetis Biosciences Ltd
Kriya Therapeutics Inc
Ligand Pharmaceuticals Inc
Merck & Co Inc
Pfizer Inc
Sanwa Kagaku Kenkyusho Co Ltd
vTv Therapeutics Inc
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles
dorzagliatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KTA-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2608204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04937319 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTP-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product Development Milestones
Featured News & Press Releases
Apr 23, 2021: Hua Medicine announces acceptance of a New Drug Application for Dorzagliatin in China - First glucokinase activator (GKA) globally
Apr 13, 2021: vTv Therapeutics receives FDA breakthrough therapy designation for TTP399 for the treatment of type 1 diabetes
Apr 12, 2021: TTP399 SimpliciT-1 study results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
Mar 23, 2021: vTv Therapeutics announces issuance of U.S. patent covering methods of treatment using TTP399
Mar 19, 2021: Milestone development achieved in clinical trials and commercialization, Hua medicine's dorzagliatin readying for NDA submission
Mar 18, 2021: vTv Therapeutics announces initiation of study evaluating TTP399’s potential to reduce risk of diabetic ketoacidosis in patients with type 1 diabetes
Feb 23, 2021: vTv Therapeutics announces publication in diabetes care of results from SimpliciT-1 study of TTP399 in patients with type 1 diabetes
Dec 18, 2020: Hua Medicine successfully completed the Phase III registration clinical study and announced the 52-week results of the DAWN study (HMM0302) of the combined use of dozaglietin and metformin
Oct 14, 2020: Hua Medicine announces the drug manufacturing permit granted for Dorzagliatin
Sep 16, 2020: vTv Therapeutics to present additional positive clinical study results from phase 2 Simplici-T1 study of TTP399 as adjunctive therapy for patients with type 1 diabetes at EASD Virtual Meeting
Jul 01, 2020: Hua Medicine announces positive 24-week topline results of phase III metformin combination trial of dorzagliatin
Jun 18, 2020: Hua Medicine successfully completes SEED (HMM0301), Dorzagliatin’s phase III Monotherapy trial
Jun 15, 2020: Hua Medicine’s Dorzagliatin demonstrates improvements in ?-Cell function in data presented at the American Diabetes Association’s 80th Scientific Sessions
Jun 13, 2020: vTv Therapeutics presents two late-breaking poster sessions on Simplici-T1 study at the American Diabetes Association’s Virtual Sessions supporting the potential of TTP399 as first-in-class oral adjunctive therapy for Type 1 Diabetes patients
May 31, 2020: Hua Medicine selected for inclusion in the MSCI Hong Kong Micro Cap Index
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Hua Medicine Shanghai Ltd, 2021
Pipeline by Impetis Biosciences Ltd, 2021
Pipeline by Kriya Therapeutics Inc, 2021
Pipeline by Ligand Pharmaceuticals Inc, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, 2021
Pipeline by vTv Therapeutics Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021